Is BPC-157 Legal? Global Status Guide
Category: Healing · Tracked in 158 countries
29
Legal1
Research Only117
Grey Area3
Prescription8
BannedCan You Buy BPC-157?
Whether you can buy BPC-157 depends on your country. It is legal to purchase in 29 countries, including Jamaica, Dominican Republic, Bahamas, Trinidad and Tobago, Barbados, Cayman Islands, Aruba, Curacao, and 21 more. A prescription is required in 3 countries, including Australia, United Arab Emirates, New Zealand. It falls into a legal grey area in 117 countries (United States, Canada, Germany, France, Netherlands, Sweden, Norway, Denmark, and 109 more), where it may be available for research but not for human use. It is banned in 8 countries: Cuba, China, Singapore, Saudi Arabia, Qatar, Bahrain, Oman, Kuwait.
Traveling with BPC-157
Traveling internationally with BPC-157 requires understanding local laws at your destination. Do not carry BPC-157 into countries where it is banned (Cuba, China, Singapore, Saudi Arabia, Qatar, Bahrain, Oman, Kuwait) — you could face serious legal consequences. In countries requiring a prescription (Australia, United Arab Emirates, New Zealand), carry a valid prescription or doctor's letter. Always declare pharmaceutical products at customs and check the latest regulations before traveling.
Need to calculate your BPC-157 dosage? Use the BPC-157 reconstitution calculator on peptide.locker
BPC-157 Legal Status by Country (158)
| Country | Status | Rx Required | Schedule | Detail |
|---|---|---|---|---|
| Anguilla | Legal | No | Not Scheduled | British OT with UK-style drug law. Peptides not scheduled. No MHRA direct enforcement. De facto unregulated. |
| Antigua and Barbuda | Legal | No | Not Scheduled | Not listed in national Misuse of Drugs Act. Not specifically regulated. General pharmaceutical law applies. |
| Aruba | Legal | No | Unregistered | Not specifically addressed by national pharmaceutical law. Falls under general medicines/drugs act. De facto grey area. |
| Bahamas | Legal | No | Unregistered | Not specifically addressed by national pharmaceutical law. Falls under general medicines/drugs act. De facto grey area. |
| Barbados | Legal | No | Unregistered | Not specifically addressed by national pharmaceutical law. Falls under general medicines/drugs act. De facto grey area. |
| Belize | Legal | No | Not Scheduled | Not scheduled under Misuse of Drugs Act. Not specifically regulated. Tourist pharmacy access high. |
| Bolivia | Legal | No | Unregistered | AGEMED has limited enforcement capacity. Peptides de facto unregulated. |
| British Virgin Islands | Legal | No | Not Scheduled | British OT with UK-style drug law. Peptides not scheduled. No MHRA direct enforcement. De facto unregulated. |
| Cayman Islands | Legal | No | Unregistered | Not specifically addressed by national pharmaceutical law. Falls under general medicines/drugs act. De facto grey area. |
| Costa Rica | Legal | No | Unregistered | Not specifically addressed by national pharmaceutical law. Falls under general medicines/drugs act. De facto grey area. |
| Curacao | Legal | No | Unregistered | Not specifically addressed by national pharmaceutical law. Falls under general medicines/drugs act. De facto grey area. |
| Dominica | Legal | No | Not Scheduled | Not listed in national Misuse of Drugs Act. Not specifically regulated. General pharmaceutical law applies. |
| Dominican Republic | Legal | No | Unregistered | Not specifically addressed by national pharmaceutical law. Falls under general medicines/drugs act. De facto grey area. |
| Grenada | Legal | No | Not Scheduled | Not listed in national Misuse of Drugs Act. Not specifically regulated. General pharmaceutical law applies. |
| Honduras | Legal | No | Not Scheduled | Not scheduled. ARSA has minimal enforcement capacity. Roatan especially relaxed. |
| Jamaica | Legal | No | Unregistered | Not specifically addressed by national pharmaceutical law. Falls under general medicines/drugs act. De facto grey area. |
| Montserrat | Legal | No | Not Scheduled | British OT with UK-style drug law. Peptides not scheduled. No MHRA direct enforcement. De facto unregulated. |
| Papua New Guinea | Legal | No | Not Scheduled | Not specifically regulated. PNG lacks capacity to evaluate novel peptides. No local market for research peptides. Import theoretically requires PSSB registration but enforcement is minimal for personal quantities. |
| Paraguay | Legal | No | Unregistered | DINAVISA minimal enforcement. Ciudad del Este is grey-market pharmaceutical hub. De facto accessible. |
| Philippines | Legal | No | Unregistered | Not FDA Philippines registered. Not specifically addressed. Grey area. |
| Samoa | Legal | No | Not Scheduled | Not specifically regulated under Samoa Pharmacy Act 2007. No local peptide market. Minimal pharmaceutical enforcement capacity. Ministry of Health has limited regulatory resources. |
| St Kitts and Nevis | Legal | No | Not Scheduled | Not listed in national Misuse of Drugs Act. Not specifically regulated. General pharmaceutical law applies. |
| St Lucia | Legal | No | Not Scheduled | Not listed in national Misuse of Drugs Act. Not specifically regulated. General pharmaceutical law applies. |
| St Vincent and the Grenadines | Legal | No | Not Scheduled | Not listed in national Misuse of Drugs Act. Not specifically regulated. General pharmaceutical law applies. |
| Tonga | Legal | No | Not Scheduled | Not specifically regulated. Tonga Pharmacy Board oversees pharmacy practice but has no specific peptide scheduling. Minimal enforcement for novel pharmaceutical imports. |
| Trinidad and Tobago | Legal | No | Unregistered | Not specifically addressed by national pharmaceutical law. Falls under general medicines/drugs act. De facto grey area. |
| Turks and Caicos | Legal | No | Not Scheduled | British OT with UK-style drug law. Peptides not scheduled. No MHRA direct enforcement. De facto unregulated. |
| Vanuatu | Legal | No | Not Scheduled | Not specifically regulated. Vanuatu Medicines and Pharmaceutical Services (VMPS) under Ministry of Health has limited enforcement capacity. No peptide scheduling or monitoring. |
| Venezuela | Legal | No | Unregistered | Severe pharmaceutical shortage. Regulatory system compromised by economic crisis. Not practically available. |
| United Kingdom | Research Only | No | Not Scheduled | Not a controlled substance under Misuse of Drugs Act 1971. Not psychoactive under PSA 2016. Legal to buy/possess for research. Illegal to sell for human consumption without MHRA authorisation. |
| Algeria | Grey Area | No | Unregistered | Not ANPP registered. Art. 179 of Law 18-11 prohibits dispensing without prescription. ANPP (est. 2018 under Art. 223) regulates all pharmaceutical products. Serialization mandatory per 2025 decree (Arrêté N°25). Drug import requires prior marketing in country of origin + third country. |
| Andorra | Grey Area | No | Not Scheduled | Not authorized by Andorran Medicines Agency (AMA). All medicines must meet quality safety and efficacy standards. Small regulatory system. Personal import of unapproved medicines permitted under certain conditions for medical need. |
| Angola | Grey Area | No | Unregistered | Not INABEC registered. Marketing Authorization from INABEC required before import/sale. Significant enforcement gaps — only 33 staff at central level, 2 inspectors per province. Research peptides not addressed. Labels must be in Portuguese. |
| Argentina | Grey Area | No | Unregistered | Not ANMAT registered. Grey area. Enforcement inconsistent due to economic constraints. |
| Austria | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. Unauthorized medicine under EU Directive 2001/83/EC. Research-label purchase tolerated in most countries. WADA banned (S0). |
| Bangladesh | Grey Area | No | Not Scheduled | Not registered with DGDA. Unregistered drugs cannot be legally manufactured or imported. DGDA is sole licensing authority under 2023 Act. No local peptide research market. Enforcement focused on counterfeit essential medicines. |
| Belgium | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. Unauthorized medicine under EU Directive 2001/83/EC. Research-label purchase tolerated in most countries. WADA banned (S0). |
| Bonaire | Grey Area | No | Not Scheduled | Dutch-style framework. Not scheduled under Opium Act BES. Unauthorized medicine if marketed for human use. De facto unregulated. |
| Bosnia and Herzegovina | Grey Area | No | Not Scheduled | Non-EU (EU candidate). ALMBIH (Agency for Medicinal Products and Medical Devices) established 2009. Complex federal structure (Federation of BiH + Republika Srpska). Not registered as medicine. Research-label purchase tolerated. WADA banned (S0). Fines 5000-15000 BAM for violations. |
| Botswana | Grey Area | No | Unregistered | Not BoMRA registered. BoMRA requires import/export permits for medicines. Research peptides not specifically addressed. Medicines Bill 2025 under constitutional challenge. BoMRA ratified African Medicines Agency treaty. |
| Brazil | Grey Area | No | Unregistered | Not ANVISA registered. Technically unauthorized. Compounding pharmacies operate under RDC 67/2007. ANVISA tightening enforcement. |
| Brunei | Grey Area | No | Not Scheduled | Not registered with BDMCA. Unregistered medicinal products cannot be marketed or imported into Brunei. Strict Islamic-influenced drug control but enforcement focused on narcotics. Peptides fall in regulatory gap. |
| Bulgaria | Grey Area | No | Not Scheduled / Unauthorized | EU member. No EMA authorization. Unauthorized medicine under EU Directive 2001/83/EC. Research-label purchase tolerated. WADA banned (S0). |
| Cambodia | Grey Area | No | Unregistered | Extremely loose enforcement. Prescription drugs widely sold OTC without prescription. Khamer Pharma manufactures peptides and steroids locally (MOH approved). Research chemicals and peptides readily available. March 2025 draft law revision may tighten rules. |
| Cameroon | Grey Area | No | Unregistered | Not registered with DPML or FDA Cameroon. Official Import Authorization (AOI) required for all approved drugs. Active anti-counterfeit enforcement — FCFA 369M in fake drugs seized H1 2025. 55 illegal medicine websites shut down. Research peptides not specifically addressed. |
| Canada | Grey Area | No | Not Scheduled (CDSA) | Unauthorized drug per Health Canada. Named in seizure notices RA-77275 (April 2025) and RA-77807 (August 2025). No DIN. Possession not criminal (not CDSA listed) but sale/import for human use illegal. |
| Cape Verde | Grey Area | No | Unregistered | Not ARFA registered. Marketing authorization governed by Regulation 09/2014 and Decree-Law 59/2006. Simplified Special Import Procedure available for unregistered medicines with doctor prescription. SIMFAR monitoring system tracks pharmaceutical market. Small island nation with limited enforcement capacity. |
| Chile | Grey Area | No | Unregistered | No ISP registration. Research peptides unaddressed. Grey area. |
| Colombia | Grey Area | No | Unregistered | Not INVIMA registered. Wellness/peptide clinics emerging in Bogota and Medellin. Low enforcement on research use. |
| Croatia | Grey Area | No | Not Scheduled / Unauthorized | EU member. No EMA authorization. BPC-157 was DISCOVERED at University of Zagreb by Prof. Predrag Sikiric (1992). Nearly all published research (~150 papers) originates from his lab. Was in IBD clinical trials (Pliva pharmaceutical). WADA banned (S0). Despite Croatian origin not approved domestically. |
| Cyprus | Grey Area | No | Not Scheduled | Not authorized by Cyprus Pharmaceutical Services (Drug Council). EU member state follows EMA framework. No marketing authorization. Cannot be legally sold for human use. Research chemical import theoretically possible under EU research exemptions. |
| Czech Republic | Grey Area | No | Not Scheduled / Unauthorized | Home of Janoshik testing lab. Major research chemical hub. Most permissive enforcement in EU. |
| Democratic Republic of Congo | Grey Area | No | Unregistered | Not ACOREP registered. Very limited regulatory capacity. ACOREP responsible for medicine quality and safety. SNAM decree (Sept 2025) reformed national drug supply system. Research peptides not addressed. Minimal enforcement outside Kinshasa. |
| Denmark | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. Unauthorized medicine under EU Directive 2001/83/EC. Research-label purchase tolerated in most countries. WADA banned (S0). |
| Ecuador | Grey Area | No | Unregistered | No ARCSA registration. Grey area. Regulatory reforms ongoing. |
| Egypt | Grey Area | No | Unregistered | EDA registration required for commercial sale. Research peptides not specifically addressed. Grey area. |
| El Salvador | Grey Area | No | Unregistered | Not scheduled but higher enforcement capacity than neighbors. SRS has broad authority. |
| Estonia | Grey Area | No | Not Scheduled / Unauthorized | EU member. No EMA authorization. Unauthorized medicine under EU Directive 2001/83/EC. Research-label purchase tolerated. WADA banned (S0). |
| Ethiopia | Grey Area | No | Unregistered | Not EFDA registered. No specific peptide regulation. Research peptides not addressed by regulatory framework. No domestic peptide market. Import would require EFDA clearance but enforcement minimal for personal quantities. |
| Fiji | Grey Area | No | Unregistered | Not registered with Fiji MRA. No specific peptide regulations. Import permit required for all medicinal products. Research chemicals not specifically addressed. Low enforcement capacity. |
| Finland | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. Unauthorized medicine under EU Directive 2001/83/EC. Research-label purchase tolerated in most countries. WADA banned (S0). |
| France | Grey Area | No | Not Scheduled / Unauthorized | Strict CSP enforcement. Personal use clearly illegal. ANSM prohibits sale/purchase for human consumption. |
| French Guiana | Grey Area | No | Unauthorized Medicine | French Code de la Sante Publique applies. Unauthorized medicine. ANSM framework. |
| Georgia | Grey Area | No | Not Scheduled | Non-EU. Independent regulatory system. Historically very liberal pharmaceutical access — many prescription drugs obtainable without Rx until 2014 tightening. Since Sept 2014 antibiotics and 6000+ medicines moved to prescription-only. However enforcement remains weak — 32.6% self-medication rate. BPC-157 falls outside current regulation. Research chemicals essentially unregulated. |
| Germany | Grey Area | No | Not Scheduled / Unauthorized | Criminal risk under Anti-Doping Act (AntiDopG 2015) if found with intent to use. Import triggers prosecution. AMG prohibits unauthorized medicine sale. |
| Ghana | Grey Area | No | Unregistered | Not FDA Ghana registered. All drugs require marketing authorization. British-influenced framework. Three-class medicine system: Class A (prescription only), Class B (pharmacist dispensed), Class C (OTC). BPC-157 not classified under any class. No domestic peptide market. FDA Ghana focused on herbal medicine regulation and food safety. |
| Greece | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. Unauthorized medicine under EU Directive 2001/83/EC. Research-label purchase tolerated in most countries. WADA banned (S0). |
| Guatemala | Grey Area | No | Unregistered | Not specifically regulated. No explicit ban or approval. Grey area. |
| Guyana | Grey Area | No | Unregistered | Not specifically regulated. No explicit ban or approval. Grey area. |
| Hong Kong | Grey Area | No | Unregistered Pharmaceutical | Not registered. Treated as unregistered pharmaceutical product. Import without authorization illegal. |
| Hungary | Grey Area | No | Not Scheduled / Unauthorized | EU member. No EMA authorization. Unauthorized medicine under EU Directive 2001/83/EC. Research-label purchase tolerated. WADA banned (S0). Hungarian Competition Authority fined C-peptide cosmetics for false medical claims (2021). |
| Iceland | Grey Area | No | WADA S2 (peptide hormones); unauthorized medicine | Not authorized by IMA. Classified under WADA S2 (peptide hormones/growth factors). PROHIBITED to import by mail/parcel delivery. Luggage import limited to 30-day supply with physician certificate. Only EMA-authorized medicines may be marketed. EEA member follows EU pharmaceutical directives. |
| India | Grey Area | No | Unregistered | India is a major peptide manufacturer. Research peptides widely available. Enforcement minimal on personal use. Pharmacies accessible. |
| Indonesia | Grey Area | No | Unregistered | Not BPOM registered. Bali has emerging wellness clinic scene. Mainland enforcement higher than Bali tourist areas. |
| Iran | Grey Area | No | Not Scheduled | Not registered with IFDA. All pharmaceutical products require IFDA regulatory approval. Sanctions complicate imports. Domestic pharma focused on essential medicines. No research peptide market. |
| Iraq | Grey Area | No | Not Scheduled | Not registered with Iraqi Directorate of Technical Affairs. All medicines require marketing authorization. However enforcement is severely weakened post-conflict. Large informal pharmaceutical market. Substandard and falsified medicines widespread in private sector. |
| Ireland | Grey Area | No | Not Scheduled / Unauthorized | 15x increase in seizures H1 2025. HPRA actively investigating online sellers. |
| Israel | Grey Area | No | Unregistered | Not MOH registered. Israeli biotech researches peptides actively but consumer access restricted. Import requires authorization. |
| Italy | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. Unauthorized medicine under EU Directive 2001/83/EC. Research-label purchase tolerated in most countries. WADA banned (S0). |
| Ivory Coast | Grey Area | No | Unregistered | Not registered with AIRP. WAEMU harmonized registration framework applies. Research peptides not specifically addressed. Registration process takes 12-24 months. Limited enforcement capacity. |
| Japan | Grey Area | No | Unapproved Drug | No PMDA approval. Treated as unapproved drug under PMD Act. No research chemical exemption. Import limited to 1-month personal supply. |
| Jordan | Grey Area | No | Unregistered | Not JFDA registered. Unauthorized drug. |
| Kenya | Grey Area | No | Unregistered | Not specifically regulated by PPB. No marketing authorization. British-influenced pharmaceutical framework. PPB focused on counterfeit medicines and GLP-1 misuse, not research peptides. No established domestic peptide research vendor market. Import from international vendors likely not intercepted. |
| Laos | Grey Area | No | Unregistered | FDD registration required on paper but enforcement weak. Pharmacies do not require prescriptions in practice. Drug classification system exists but not enforced for peptides. |
| Latvia | Grey Area | No | Not Scheduled / Unauthorized | EU member. No EMA authorization. Unauthorized medicine under EU Directive 2001/83/EC. Research-label purchase tolerated. WADA banned (S0). |
| Lebanon | Grey Area | No | Not Scheduled | Not registered with MOPH Drug Registration Technical Committee. All pharma products must be registered at MOPH. Economic crisis has severely weakened pharmaceutical regulation and enforcement. Drug shortages widespread. |
| Libya | Grey Area | No | Unregistered | Not NCDCR registered. Libya lacks formal drug scheduling system. Pharmaceutical Affairs Dept handles registration/licensing. GS1 DataMatrix barcodes mandatory for all pharma imports per Decision 379/2023. Ongoing instability limits enforcement. |
| Liechtenstein | Grey Area | No | Not Scheduled | Not authorized. Liechtenstein is EEA member (EFTA). Follows EU pharmaceutical acquis via EEA Agreement. Accepts EMA centrally authorized products. No national authorization for BPC-157. Regulatory alignment with Austria. |
| Lithuania | Grey Area | No | Not Scheduled / Unauthorized | EU member. No EMA authorization. Unauthorized medicine under EU Directive 2001/83/EC. Research-label purchase tolerated. WADA banned (S0). |
| Luxembourg | Grey Area | No | Not Scheduled | No marketing authorization. EU member state follows EMA framework. Pharmacy and Medication Department of National Health Directorate oversees pharmaceutical regulation. Luxembourg establishing ALMPS (national medicines agency). |
| Madagascar | Grey Area | No | Unregistered | Not AMM registered. Research peptides not addressed by AMM. Market Authorization (AMM) required for all medicines per Art. 4 of Decree 2010-960. Minimal enforcement capacity outside Antananarivo. |
| Malawi | Grey Area | No | Unregistered | Not PMRA registered. PMRA (est. 2019, replacing PMPB) regulates medicines, pharmacy professions, and pharmaceutical businesses. Research peptides not specifically addressed. Clinical Trials Amendment Regulations 2025 signed April 2025. |
| Malaysia | Grey Area | No | Unregistered | NPRA registration required. Not approved. Grey area but enforcement moderate. |
| Maldives | Grey Area | No | Unregistered | MFDA registration required for all medicines. Not registered. Import requires MFDA authorization. Physical inspection at port of entry. No postal import of pharmaceuticals allowed. |
| Malta | Grey Area | No | Unauthorized Medicine | EU member state. Full harmonization with EU pharmaceutical law. Any compound for human therapeutic use requires EMA or MMA marketing authorization. Research chemicals not authorized for human consumption. Import from non-EU requires Manufacturer's Authorization for Import (MIA). Borderline Classification Committee determines medicine vs non-medicine status. |
| Mauritius | Grey Area | No | Unregistered | All pharmaceutical products imported only by licensed wholesalers through Pharmacy Board. BPC-157 not specifically regulated. Personal medicine import allowed with doctor's note (3-month supply prescription, 1-month controlled). No domestic peptide market. Medical tourism destination but peptide clinics not established. |
| Mexico | Grey Area | No | Unregistered | Not COFEPRIS registered. Sold at research vendors. Clinics in Tijuana/Puerto Vallarta/Cancun openly administer. Major peptide tourism destination. |
| Monaco | Grey Area | No | Not Scheduled | Monaco follows French pharmaceutical law via 1963 bilateral convention. DASS (Direction de l'Action Sanitaire et Sociale) cooperates with French ANSM. No marketing authorization. Same status as in France — unauthorized medicinal product. |
| Montenegro | Grey Area | No | Not Scheduled | Non-EU (EU candidate). Independent regulatory system aligning with EU. CALIMS/CInMED regulates. Not registered as medicine. Research-label purchase tolerated. WADA banned (S0). Low enforcement capacity. |
| Morocco | Grey Area | No | Unregistered | No specific peptide regulation. All pharmaceutical products require Marketing Authorization (AMM) from DMP/AMMPS. BPC-157 has no AMM. No domestic peptide vendor market. French-influenced pharma law treats unregistered medicines strictly. Import for personal use requires medical justification. |
| Mozambique | Grey Area | No | Unregistered | Not ANARME registered. No specific peptide regulation. Research peptides not addressed. ANARME established 2019 as autonomous regulatory body. Still building regulatory capacity. |
| Myanmar | Grey Area | No | Unregistered | Virtually no enforcement. All prescription drugs including steroids and antibiotics sold OTC. FDA Myanmar has minimal inspection capacity. Budget constraints prevent active monitoring. Drug shops operate without licensed pharmacists. |
| Namibia | Grey Area | No | Unregistered | All medicines require NMRC registration. South African-influenced regulatory framework (both use similar Medicines Act structure). NMRC has quality surveillance laboratory. Personal import of scheduled substances for medicinal use permitted in specified quantities. Currently reviewing/strengthening regulatory framework with WHO assistance (Oct 2025 self-benchmarking). |
| Nepal | Grey Area | No | Unregistered | DDA registration required but enforcement weak. Drug Act classifies hormones under Category KHA (b) requiring prescription. Peptides not specifically categorized. Online pharmacies deliver prescription medicines without prescriptions. |
| Netherlands | Grey Area | No | Not Scheduled / Unauthorized | Major vendor hub but Feb 2026 IGJ warning issued. Enforcement increasing. Research purchases tolerated but investigated. |
| Nicaragua | Grey Area | No | Unregistered | Not specifically regulated. No explicit ban or approval. Grey area. |
| Nigeria | Grey Area | No | Unregistered | Not NAFDAC registered. All pharmaceutical products must be registered before manufacture, import, or sale. British-influenced framework. NAFDAC enforcement focused heavily on counterfeit antimalarials, antibiotics, and now GLP-1 counterfeits. Research peptides not a priority. No domestic peptide vendor market. NAFDAC closed 11,000+ shops in counterfeit crackdowns but focused on mainstream drugs. |
| North Macedonia | Grey Area | No | Not Scheduled | Non-EU (EU candidate since 2005). MALMED (Agency for Medicines and Medical Devices) established 2014. Not registered as medicine. Research-label purchase tolerated. WADA banned (S0). Pharmaceutical tourism to Kosovo/Serbia for cheaper drugs common. |
| Norway | Grey Area | No | Not Scheduled / Unauthorized | Unauthorized medicine. Import for personal use prohibited without prescription. |
| Pakistan | Grey Area | No | Not Scheduled | Not registered with DRAP. Pakistan has large generic pharma industry but focused on conventional drugs. Peptide research chemicals not a significant market. Enforcement focused on counterfeit/substandard essential medicines. |
| Panama | Grey Area | No | Unregistered | Not scheduled. Clinical peptide use at wellness/regenerative clinics (Auragens, BioGenesis, Regenerate Panama). Grey area low risk. |
| Peru | Grey Area | No | Unregistered | No DIGEMID registration or ban. Unregistered grey area. Enforcement low. |
| Poland | Grey Area | No | Not Scheduled / Unauthorized | Major EU peptide distribution hub. Enforcement permissive. Research vendors operate widely. |
| Portugal | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. Unauthorized medicine under EU Directive 2001/83/EC. Research-label purchase tolerated in most countries. WADA banned (S0). |
| Romania | Grey Area | No | Not Scheduled / Unauthorized | EU member. No EMA authorization. Unauthorized medicine under EU Directive 2001/83/EC. Research-label purchase tolerated. WADA banned (S0). Low enforcement on research peptides. |
| Russia | Grey Area | No | Unregistered | Not officially registered. Available from Russian research suppliers. Grey area. |
| Rwanda | Grey Area | No | Unregistered | All regulated products must be Rwanda FDA registered before import/sale. Applications require effectiveness, safety, and quality data. Rwanda FDA has WHO ML3 maturity (achieved Dec 2024). First AU Member State to sign African Medicines Agency treaty (2019). EAC harmonization for abbreviated registration procedures. No domestic peptide market. |
| Saba | Grey Area | No | Not Scheduled | Dutch-style framework. Not scheduled under Opium Act BES. Unauthorized medicine if marketed for human use. De facto unregulated. |
| Saint Barthelemy | Grey Area | No | Unauthorized Medicine | French Code de la Sante Publique applies. Unauthorized medicine. Personal use illegal. Limited local enforcement. |
| Saint Martin (French) | Grey Area | No | Unauthorized Medicine | French Code de la Sante Publique applies. Unauthorized medicine. Personal use illegal. Limited local enforcement. |
| Senegal | Grey Area | No | Unregistered | French-influenced pharma law. All medicines require marketing authorization from DPL. Import of unapproved medicines for personal use requires Ministry of Health special authorization with medical justification. Pharmacy Inspection Office conducts facility inspections. WHO ML3 regulatory maturity (first francophone country). No domestic peptide market. |
| Serbia | Grey Area | No | Not Scheduled | Non-EU. Independent regulatory system (ALIMS). No EMA framework. BPC-157 not registered as medicine. Research-label purchase tolerated. Pharmacies known to sell prescription drugs without Rx. ~33% of Rx drugs obtained without prescription. |
| Seychelles | Grey Area | No | Unregistered | No medicine registration system exists. Limited inspection activities. Pharmaceuticals reportedly easy to buy with few controls. Import permit technically required but enforcement weak. |
| Sint Eustatius | Grey Area | No | Not Scheduled | Dutch-style framework. Not scheduled under Opium Act BES. Unauthorized medicine if marketed for human use. De facto unregulated. |
| Sint Maarten | Grey Area | No | Not Scheduled | Dutch-style framework. Not scheduled under Opium Act BES. Unauthorized medicine if marketed for human use. De facto unregulated. |
| Slovakia | Grey Area | No | Not Scheduled / Unauthorized | EU member. No EMA authorization. Unauthorized medicine under EU Directive 2001/83/EC. Research-label purchase tolerated. WADA banned (S0). |
| Slovenia | Grey Area | No | Not Scheduled / Unauthorized | EU member. No EMA authorization. Unauthorized medicine under EU Directive 2001/83/EC. Research-label purchase tolerated. WADA banned (S0). Slovenian researchers involved in BPC-157 research alongside Croatian University of Zagreb team. |
| South Africa | Grey Area | No | Unregulated | Not a scheduled substance. Not specifically regulated by SAHPRA. Sold openly by SA research peptide vendors (peptides.co.za, BioHck, Protopep, Ultra Labs) as 'research chemical, not for human use.' Multiple clinics (Dr Thys Heyns, Medify, Premier Body) offer peptide therapy protocols. SAHPRA states peptides are 'not currently regulated' but 'may introduce regulatory changes.' WADA prohibited. |
| South Korea | Grey Area | No | Unapproved Drug | Not MFDS approved. Unapproved drug under Pharmaceutical Affairs Act. No research chemical loophole. |
| Spain | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. Unauthorized medicine under EU Directive 2001/83/EC. Research-label purchase tolerated in most countries. WADA banned (S0). |
| Sri Lanka | Grey Area | No | Unregistered | NMRA registration required for all medicines. Not registered. Products must have prior approval from US FDA/Health Canada/EMA/TGA. WHO GMP mandatory. Import without authorization prohibited. Personal use import limited to 100 doses with NMRA Letter of Authorization. |
| Suriname | Grey Area | No | Unregistered | Not specifically regulated. No explicit ban or approval. Grey area. |
| Sweden | Grey Area | No | Not Scheduled / Unauthorized | Doping Act (Dopningslagen) criminalizes personal USE. Customs actively seize. INTERPOL 2025 seizures. |
| Switzerland | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. Unauthorized medicine under EU Directive 2001/83/EC. Research-label purchase tolerated in most countries. WADA banned (S0). |
| Taiwan | Grey Area | No | Unapproved Drug | Not TFDA approved. Unapproved drug. Import restricted. |
| Tanzania | Grey Area | No | Unregistered | All products must be TMDA registered before import/sale. TMDA has Scheduling of Medicines Regulations (updated Dec 2025). BPC-157 not specifically listed. Import requires premises registration and import permits via online trader portal. TMDA achieved WHO ML3 regulatory maturity. More structured than some regional peers. |
| Thailand | Grey Area | No | Unregistered | Not Thai FDA registered but widely available at Bangkok wellness/anti-aging clinics. Medical tourism hub. Low enforcement on research peptides. |
| Tunisia | Grey Area | No | Unregistered | French-influenced pharma law. All medicines require Marketing Authorization from DPM. BPC-157 has no MA. No domestic peptide research market. DPM controls import of all drugs including biologics. WHO Collaborating Center for medicine registration since 1998. |
| Turkey | Grey Area | No | Unregistered | Not TITCK registered. Medical tourism sector growing. Some wellness clinics emerging. Grey area. |
| Uganda | Grey Area | No | Unregistered | Not NDA registered. No specific peptide regulation. Research chemicals not addressed. No domestic peptide market. NDA focused on essential medicines and counterfeit prevention. |
| Ukraine | Grey Area | No | Not Scheduled | Non-EU. Independent regulatory system. SMDC oversees pharmaceutical regulation. Wartime adaptations since 2022 — simplified registration for medicines from EU/UK/US/Switzerland/Japan/Australia/Canada/WHO. BPC-157 not registered. Research-label available. Enforcement resources diverted to war effort. |
| United States | Grey Area | No | Not Scheduled | Not a controlled substance. FDA banned from compounding pharmacies (Category 2 list). Sold as 'research chemical' but FDA actively issuing warning letters (Dec 2024/2025). Possession not criminal. Sale for human use violates FDCA. |
| Uruguay | Grey Area | No | Unregistered | MSP registration required for commercial sale. Research peptides in grey zone. Liberal regulatory culture. |
| US Virgin Islands | Grey Area | No | Not Scheduled | Same as US federal law. FDA Category 2 — banned from compounding. Research sale tolerated but enforced. |
| Vietnam | Grey Area | No | Unregistered | DAV registration required. Unauthorized drug. Not commonly available. |
| Zambia | Grey Area | No | Unregistered | Not ZAMRA registered. ZAMRA requires registration for all medicines imported/sold. Research peptides not specifically addressed. Signed MOU with MCAZ (Zimbabwe) June 2025. Working toward WHO ML3. |
| Zimbabwe | Grey Area | No | Unregistered | Not MCAZ registered. MCAZ is well-established and actively enforces pharmaceutical regulations. Research peptides not specifically addressed but import/sale without MCAZ authorization illegal. Traceability guidelines (MCAZ/LED/GL-22) effective July 2025. |
| Australia | Prescription | Yes | Schedule 4 + Appendix D Item 5 | Schedule 4 (Prescription Only) + Appendix D Item 5 effective 1 June 2024. Possession without valid prescription is criminal offence. Access only via Special Access Scheme (SAS) or Authorised Prescriber pathway. |
| New Zealand | Prescription | Yes | Unapproved (Rx Required) | Not Medsafe approved. Classified as prescription medicine under Medicines Act 1981. Personal import up to 3-month supply requires valid NZ prescription. |
| United Arab Emirates | Prescription | Yes | Clinic Prescribed | Available ONLY through DHA-licensed clinics (Hortman, Novomed, IVHUB, DNA Health Corp). Not for OTC sale. Do NOT import personally — strict customs. |
| Bahrain | Banned | No | Unauthorized | Not NHRA registered. Unauthorized. Do not import. |
| China | Banned | No | Unapproved Drug | NMPA does not approve. No consumer research market. China is major manufacturer/exporter but domestic use unauthorized. 2025 export restrictions on certain peptides. |
| Cuba | Banned | No | State Controlled | State pharmaceutical monopoly via CECMED/BioCubaFarma. No private purchase/import permitted. |
| Kuwait | Banned | No | Unauthorized | Not registered. Unauthorized. Do not import. |
| Oman | Banned | No | Unauthorized | Not registered. Unauthorized import. Do not import. |
| Qatar | Banned | No | Unauthorized | Not registered. Unauthorized import. Strict customs. Do not import. |
| Saudi Arabia | Banned | No | Unauthorized | Not SFDA registered. Unauthorized import. Very strict customs. Do NOT import. |
| Singapore | Banned | No | Unapproved Health Product | HSA classifies as unapproved health product. Import/sale/possession without authorization illegal. Singapore has ZERO tolerance drug policy. Do NOT import. |
Data is researcher-verified but not legal advice. Regulations change frequently. Always verify with local authorities before purchasing, importing, or traveling with peptides. Last verified: 2026-02-28.